Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials.
Continue Reading→The location of telangiectases in hereditary hemorrhagic telangiectasia (HHT), as set forth in the consensus diagnostic (Curaçao) criteria, is based primarily on adults.
Continue Reading→Radiation dermatitis is a common sequela of radiation therapy; up to 95% of patients will develop moderate-to-severe skin reactions. No gold-standard currently exists for the treatment of acute radiation-induced skin toxicity. It is, therefore, imperative to develop a greater understanding…
Continue Reading→